Volatility of vaccine confidence
Heidi J. Larson, David Broniatowski
Abstract
Last week, the European Medicines Agency declared the AstraZeneca COVID-19 vaccine safe and effective, after several European Union member states had suspended its use because of blood clot concerns. Will the public trust this message? This week's news could help—a U.S. phase 3 clinical trial of the vaccine shows promising efficacy in preventing symptomatic COVID-19. But sentiments toward vaccines are volatile and reflect external events—such as recent concern about AstraZeneca's efficacy data—as well as internal emotions.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)European unionVolatility (finance)Member statesAgency (philosophy)MedicineClinical trial2019-20 coronavirus outbreakBusinessFamily medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakFinanceDiseasePhilosophyEpistemologyEconomic policySARS-CoV-2 and COVID-19 ResearchHealth Systems, Economic Evaluations, Quality of LifeEmpathy and Medical Education